Pancreatic Cancer Treatment Market

• Market Size (2023): USD 2.86 billion

• Market Size (2024): USD 3.30 billion

• Market Size (2032): USD 10.69 billion

• CAGR (2024-2032): 15.8%

• U.S. Market Size (2032): USD 5.25 billion

Key Market Insights

• The market is driven by the increasing incidence of pancreatic cancer globally and the rising geriatric population.

• Companies are increasing R&D activities and receiving approvals for new drugs.

• The COVID-19 pandemic initially slowed market growth but is now recovering.

Market Trends

• Presence of potential pipeline products is driving market growth.

• Key players are shifting focus to extensive R&D activities.

• Increased funding for cancer research is leading to new drug development.

• Scientists are focusing on developing personalized medicines for pancreatic cancer treatment.

Market Growth Factors

• Increasing prevalence of pancreatic cancer.

• Increasing regulatory approvals of novel targeted therapies.

• Launches of immunotherapies in combination with chemotherapies.

• Supportive government policies and funding for research.

• Efforts to raise awareness about pancreatic cancer.

Restraining Factors

• High cost of pancreatic cancer treatment.

• Side effects associated with chemotherapy and radiation therapy.

Market Segmentation Analysis

• By Type:

  • Exocrine (largest market share in 2023)

  • Endocrine

• By Treatment Type:

  • Chemotherapy (largest market share in 2023)

  • Radiation Therapy

  • Others

• By End-user:

  • Hospitals (largest market share in 2023)

  • Clinics

  • Others

Regional Insights

• North America:

  • Market Size (2023): USD 1.35 billion

  • Presence of advanced healthcare facilities and adoption of new technologies.

  • Increasing prevalence of pancreatic cancer in the U.S.

• Europe:

  • Second-largest market share.

  • High prevalence of pancreatic cancer in Germany, France, Italy, and Spain.

  • Increase in R&D investment and favorable government regulations.

• Asia Pacific:

  • Anticipated to expand at the highest CAGR.

  • Rising prevalence, improving healthcare infrastructure, and increasing number of pharmaceutical companies.

• Middle East & Africa and Latin America:

  • Likely to grow at a slower pace.

  • Increase in geriatric population and prevalence of pancreatic cancer.

List of Key Companies

• AstraZeneca (U.K.)

• Novartis AG (Switzerland)

• Pfizer Inc. (U.S.)

• Genentech (F. Hoffmann-La Roche Ltd) (U.S.)

• Bristol-Myers Squibb Company (U.S.)

• Ipsen Pharma (France)

• Oncolytics Biotech, Inc. (Canada)

• TME Pharma (Germany)

• Erytech Pharma (France)

• Clovis Oncology, Inc. (U.S.)  

• 
  

Key Industry Developments

• February 2024: Fast-track designation granted for IMM-1-104 by the U.S. FDA for pancreatic cancer treatment.

• January 2022: Novartis AG received Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA.

• September 2021: F. Hoffmann-La Roche Ltd partnered with NovoCure to develop Tumor Treating Fields (TTFields).

• December 2020: Bristol-Myers Squibb Company announced positive results from the phase III clinical trial, CheckMate – 548.

• June 2020: Ipsen pharma received fast-track designation by the U.S. FDA for the use of liposomal irinotecan (ONIVYDE).

• December 2019: AstraZeneca and Merck & Co. Inc. received U.S. FDA approval for Lynparza (olaparib).

Last Updated: October 14, 2024 | Format: PDF | Report ID: FBI101989

Source: https://www.fortunebusinessinsights.com/pancreatic-cancer-treatment-market-101989